Results 111 to 120 of about 49,499 (264)

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Amylin: A Multi‐Functional Pancreatic Hormone—A Review

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Amylin is a pancreatic beta‐cell hormone that sits at a systems hub connecting key aspects of energy metabolism. Amylin physiologically controls satiation, slows gastric emptying and limits postprandial glucagon release, while its actions also link homeostatic eating controls with reward driven behaviours via defined central nervous system ...
Christelle Le Foll, Thomas A. Lutz
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Tobacco industry influence on breast cancer research, policy and public opinion: scoping the Truth Tobacco Industry Documents. [PDF]

Tob Control
Han E, Crosbie E, Ling P, Perez S, Khan H, Hiatt R, Kearns C.   +6 more
europepmc   +1 more source

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Endoscopic Versus Open Carpal Tunnel Release in Obese and Nonobese Patients. [PDF]

J Hand Surg Glob Online
Salib A, Sanchez JG, Diatta F, Zehner KM, Kong V, Grauer JN, Colen D.   +6 more
europepmc   +1 more source

CTR MEETS REALITY [PDF]

Journal of Neurology and Neuromedicine, 2018
openaire   +1 more source

Unpacking the relationship between co‐creation and brand equity: A multi‐study approach

European Management Review, EarlyView.
Abstract Whilst some studies have shown that co‐creation positively influences brand equity, others have found only marginal or even negative effects, and several failure cases of co‐creation have been reported. To overcome the confusion generated by mixed findings, this paper unpacks the relationship between co‐creation and brand equity, considering ...
Stefan Markovic, Oriol Iglesias, Anna Torres, Pilar Rivera‐Torres, Nikolina Koporcic   +4 more
wiley   +1 more source

Structural mechanism of SAM-AMP and SAM-AMP₂ synthesis by the type III-D2 CRISPR effector complex. [PDF]

Nat Commun
Mitsuda Y, Sugaya M, Ishikawa J, Nagahata N, Okazaki S, Hiraizumi M, Kato K, Gootenberg JS, Abudayyeh OO, Osawa T, Yamashita K, Nishimasu H.   +11 more
europepmc   +1 more source

Iloperidone treatment mitigates the Juvenile Huntington's Disease phenotype possibly via Sigma‐1 Receptor Modulation

The FEBS Journal, EarlyView.
We investigated the potential of iloperidone as an activator of Sigma‐1 receptor (S1R) neuroprotective function in juvenile Huntington's disease (jHD). We tested iloperidone on cortical neurons differentiated from patient‐derived iPSCs, demonstrating that it acts as a S1R agonist, decreasing apoptosis, huntingtin aggregation, and oxidative stress ...
Ersilia Fornetti, Gaia Galluzzi, Mario Frezzini, Cécile Exertier, Vittorio Brufani, Gianni Colotti, Giancarlo Ruocco, Jessica Rosati, Angelo Luigi Vescovi, Daniele Narzi, Ilaria Genovese, Andrea Ilari   +11 more
wiley   +1 more source